Indaptus Therapeutics filings document a clinical-stage biotechnology issuer developing Decoy20 and related immunotherapy programs for cancer and viral infections. The company’s regulatory record includes material-event reports, proxy statements, capital-structure disclosures, and governance filings tied to its Nasdaq-listed common stock.
Key filing subjects include convertible preferred stock, warrants, warrant repricing agreements, voting agreements, unregistered securities, shareholder meeting proposals, and changes in control. The filings also cover board and officer appointments or resignations, compensatory arrangements, operating and financial results, and material agreements that affect the company’s financing, governance, and public-company structure.
Indaptus Therapeutics’ major shareholder David E. Lazar has sharply reduced his economic stake and stepped down as co‑Chief Executive Officer while remaining on the Board. He entered a March 2026 securities purchase agreement to sell 700,000 shares of Series AAA Preferred Stock and 196,800 shares of Series AA Preferred Stock for an aggregate $11,200,000.
These preferred shares are convertible into a total of 108,936,000 common shares. After closing on March 23, 2026, Lazar retains 103,200 Series AA Preferred shares, convertible into 2,064,000 common shares. Based on 2,242,324 common shares outstanding as of March 16, 2026 plus his remaining convertibles, the filing reports beneficial ownership of approximately 47.93%, which would drop to about 1.82% after other purchasers convert their preferred stock.
Indaptus Therapeutics director David E. Lazar sold a large block of the company’s convertible preferred stock. On March 23, 2026, he completed a Securities Purchase Agreement under which he sold all 700,000 shares of Series AAA Preferred Stock, which were convertible into 105,000,000 shares of common stock, and 196,800 shares of Series AA Preferred Stock, which were convertible into 3,936,000 shares of common stock. Following this transaction, he retained 103,200 shares of Series AA Preferred Stock, convertible into 2,064,000 shares of common stock. Both the Series AA and Series AAA Preferred Stock are perpetual and convertible at the holder’s option for no additional consideration.
Indaptus Therapeutics reports a transformative year marked by a recapitalization, governance changes and a halt to clinical development. On December 22, 2025 it sold 300,000 Series AA and 700,000 Series AAA preferred shares to David E. Lazar for $6.0 million, each share priced at $6.00. These series are convertible into a combined 111,000,000 common shares, and Mr. Lazar is now the beneficial owner of about 96.4% of the company’s common stock on an as-converted, fully diluted basis.
Stockholders approved a large increase in authorized common shares to 1,000,000,000, a reverse stock split range, and board changes that installed multiple Lazar designees. The company repriced roughly 1.68 million warrants to an exercise price of $1.75 per share and used ATM sales, a $5.7 million convertible note, equity lines and several 2024–2025 equity/warrant financings to raise cash.
Indaptus, a clinical-stage immunotherapy developer, discontinued enrollment in its Decoy20 monotherapy and combination trials and has no current plans to start new clinical studies. It discloses substantial doubt about its ability to continue as a going concern and is evaluating a strategic transaction to invest in or acquire a target company.
Indaptus Therapeutics Inc. investor David E. Lazar has disclosed effective control of the company, reporting beneficial ownership of 111,000,000 shares of common stock, or about 98% of the class, through convertible preferred stock.
Under a Securities Purchase Agreement dated December 22, 2025, Lazar agreed to buy 300,000 shares of Series AA Preferred Stock, convertible into 6 million common shares for $1.8 million, and 700,000 shares of Series AAA Preferred Stock, convertible into 105 million common shares for $4.2 million, for total consideration of $6 million. Stockholders approved the necessary share increase and conversion on February 26, 2026.
Following this deal, Lazar became Co-Chief Executive Officer and a director, and is expected to serve as Chairman of the Board. He also obtained the right to recommend up to three additional director nominees at a future stockholder meeting and has participation rights in future Indaptus financing transactions.
Jabbour Jerome D reported acquisition or exercise transactions in this Form 4 filing.
Indaptus Therapeutics director receives stock option grant. Indaptus Therapeutics, Inc. granted director Jerome D. Jabbour options to buy 25,000 shares of common stock under its non-employee director compensation program. These options vest over three years in equal quarterly installments, conditioned on his continued service on the board.
Indaptus Therapeutics reports that stockholders approved a set of proposals that enables a change in control, large potential share issuance and structural changes to its charter and bylaws.
Following a prior preferred stock investment by David E. Lazar, stockholders approved issuing common shares upon conversion of 300,000 Series AA and 700,000 Series AAA Convertible Preferred Stock. After the related charter amendment filing, these preferred shares are convertible at Mr. Lazar’s option into 111.0 million common shares, representing about 96.4% of common stock on a fully diluted basis.
Stockholders also authorized the board to implement up to two reverse stock splits in a 1‑for‑2 to 1‑for‑199 range, approved increasing authorized common shares to 1,000,000,000 and allowed stockholder action by written consent. Two directors, Jerome Jabbour and Matthew McMurdo, were elected, giving Mr. Lazar’s nominees a majority of the nine‑member board.
Indaptus Therapeutics, Inc. filed an initial insider ownership report for board member Jerome D. Jabbour on Form 3. This filing establishes his status as a director subject to insider reporting rules. The report does not list any buy, sell, or other share transactions.
Indaptus Therapeutics, Inc. director Matthew Charles McMurdo reported his initial ownership of the company’s common stock. He holds 25,000 shares of common stock directly, as shown in this initial statement of beneficial ownership.
Indaptus Therapeutics Co-Chief Executive Officer and director Jeffrey Meckler reported derivative warrant transactions tied to a board-approved repricing. On February 11, 2026, previously held warrants were disposed of back to the company and replacement warrants were acquired on a direct ownership basis.
The transactions cover several warrant series exercisable for common stock, with the board unilaterally reducing the per-share exercise price of all affected warrants to $1.75 while leaving all other terms unchanged. Following the dispositions and matching acquisitions, Meckler directly holds new warrants for 3,033, 1,519, and 12,136 underlying shares at the revised exercise price.
The filing also notes that on June 26, 2025, Indaptus implemented a 1-for-28 reverse stock split of its common stock, and all warrant amounts in the report reflect this adjustment.
Indaptus Therapeutics entered into warrant repricing agreements with certain holders of warrants to purchase an aggregate 913,638 shares of common stock that were originally issued in 2024 and 2025 at exercise prices ranging from $8.30 to $47.60. The company reduced the exercise price of these warrants to $1.75 per share, which matches the Nasdaq-defined “Minimum Price.” In return, these holders agreed under a voting agreement to vote all their common shares in favor of all proposals at a special stockholder meeting scheduled for February 26, 2026. The board also unilaterally reduced the exercise price to $1.75 for additional warrants and placement agent warrants to purchase an aggregate 762,787 shares from the same financing rounds, leaving all other warrant terms unchanged.